The present study also illustrated that the FAM57A expression level was directly correlated with the clinical stage, pathological grade and T stage, which suggested that HCC patients with high FAM57A expression were more likely to experience progression to advanced stages. This evidence concerns the gene TLCD3A and hepatocellular carcinoma.